NCT03233217 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years | Biotech Hunter

Enrollment

175

Participants

Timeline

Start Date

September 15, 2017

Primary Completion Date

November 28, 2017

Study Completion Date

November 28, 2017

Conditions

Influenza

Interventions

BIOLOGICAL

QIV-HD by IM

IM, injected into the upper arm (deltoid area)

BIOLOGICAL

QIV-SD by SC

SC, injected into the upper arm (posterior region)

BIOLOGICAL

QIV-HD by SC

SC, injection into the upper arm (posterior region)

Trial Locations (2)

Sanofi Pasteur Investigational Site, Ōsaka

Sanofi Pasteur Investigational Site, Tokyo